Samuel Kintz - 17 Nov 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: ELVN
Reported as of: 17 Nov 2025
Net transaction value: -$272,739
SEC form: 4
Accepted by SEC: 19 Nov 2025, 18:45:15 UTC
Prior SEC filing: 21 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Samuel Kintz filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 19 Nov 2025.

Key facts

This page summarizes Samuel Kintz's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Nov 2025, 18:45.

Change

Previous filing in this sequence was filed on 21 Oct 2025.
Current net transaction value: -$272,739.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001967168 Primary reporting owner

Kintz Samuel

Relationship: PRESIDENT AND CEO, Director
Address: C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 19 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Sale

Transaction value: $272,739
Shares: -12,500
Change %: -1.4%
Price: $21.82
Shares after: 890,392
Date: 17 Nov 2025
Ownership: See footnote
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.